EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial

Lars Rejnmark, Elvira O Gosmanova, Aliya A Khan, Noriko Makita, Yasuo Imanishi, Yasuhiro Takeuchi, Stuart Sprague, Dolores M Shoback, Lynn Kohlmeier, Mishaela R Rubin, Andrea Palermo, Peter Schwarz und 9 weitere

Advances in Therapy · 2024-06 · 41 (6) · 2500-2518

DOI: 10.1007/s12325-024-02843-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, online erschienen am 30.04.2024. Verfasst von Lars Rejnmark und 20 weiteren Autor:innen. Beteiligte Einrichtung: Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Hypoparathyroidism, Parathyroid Hormone, Peptides. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Individuals with chronic hypoparathyroidism managed with conventional therapy (active vitamin D and calcium) have an increased risk for renal dysfunction versus age- and sex-matched controls. Treatments that replace the physiologic effects of parathyroid hormone (PTH) while reducing the need for conventional therapy may help prevent a decline in renal function in this population. This post hoc analysis examined the impact of palopegteriparatide treatment on renal function in adults with chronic hypoparathyroidism. METHODS: PaTHway is a phase 3 trial of palopegteriparatide in adults with chronic hypoparathyroidism that included a randomized, double-blind, placebo-controlled 26-week period followed by an ongoing 156-week open-label extension (OLE) period. Changes in renal function over 52 weeks (26 weeks blinded + 26 weeks OLE) were assessed using estimated glomerular filtration rate (eGFR). A subgroup analysis was performed with participants stratified by baseline eGFR 600 mg/day]). After 52 weeks of treatment with palopegteriparatide, significant improvements were seen in a measure of kidney function called estimated glomerular filtration rate (eGFR). Improvements in eGFR from the beginning of the trial to week 52 were considered clinically meaningful for over 57% of participants. In participants with impaired kidney function at the beginning of the trial, eGFR improvements were even greater, and 74% of participants had a clinically meaningful improvement. These results suggest that palopegteriparatide treatment may be beneficial for kidney function in adults with chronic hypoparathyroidism, especially those with impaired kidney function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerular Filtration RateHypoparathyroidismParathyroid HormonePeptidesAdultAgedFemaleHumansMaleMiddle AgedCalciumChronic DiseaseDouble-Blind MethodTreatment OutcomeVitamin D

Stichwörter der Autor:innen

Clinical trialGlomerular filtration rateHypoparathyroidismKidneyPalopegteriparatideParathyroid hormoneRenal diseaseTransCon PTH

Substanzen

CalciumParathyroid HormoneVitamin DPeptidesPalopegteriparatide

Autor:innen und Institutionen

  • Aarhus University Hospital, Aarhus, Denmark.
  • Albany Medical College, Albany, NY, USA.
  • McMaster University, Hamilton, ON, Canada.
  • The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

ORCID-Profile: Aimee D Shu

Zitieren

APA

Rejnmark, L., Gosmanova, E. O., Khan, A. A., Makita, N., Imanishi, Y., Takeuchi, Y., Sprague, S., Shoback, D. M., Kohlmeier, L., Rubin, M. R., Palermo, A., Schwarz, P., Gagnon, C., Tsourdi, E., Zhao, C., Makara, M. A., Ominsky, M. S., Lai, B., Ukena, J., …, & Shu, A. D. (2024). Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Advances in Therapy, 41(6), 2500-2518. https://doi.org/10.1007/s12325-024-02843-8

Vancouver

Rejnmark L, Gosmanova EO, Khan AA, Makita N, Imanishi Y, Takeuchi Y, et al. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Advances in Therapy. 2024;41(6):2500-2518. doi:10.1007/s12325-024-02843-8

BibTeX
@article{Rejnmark2024,
  author = {Rejnmark, Lars and Gosmanova, Elvira O and Khan, Aliya A and Makita, Noriko and Imanishi, Yasuo and Takeuchi, Yasuhiro and Sprague, Stuart and Shoback, Dolores M and Kohlmeier, Lynn and Rubin, Mishaela R and Palermo, Andrea and Schwarz, Peter and Gagnon, Claudia and Tsourdi, Elena and Zhao, Carol and Makara, Michael A and Ominsky, Michael S and Lai, Bryant and Ukena, Jenny and Sibley, Christopher T and Shu, Aimee D},
  title = {Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial},
  journal = {Advances in Therapy},
  year = {2024},
  volume = {41},
  number = {6},
  pages = {2500--2518},
  doi = {10.1007/s12325-024-02843-8}
}
Kostenlos starten →